The Indian pharmaceutical industry is facing significant supply risks amid the ongoing conflict in West Asia, despite the government's recent decision to waive customs duties on over 40 petrochemical products until June 30. Industry experts, including Mehul Shah, emphasize that while the waiver offers some cost relief, the primary concern is the timely supply and movement of essential materials. The declaration of force majeure by Saudi chemical giant SABIC on methanol and styrene further underscores the industry's supply challenges. Rajiv Nath from the Association of Indian Medical Devices Industry (AiMeD) noted that the government's intervention aims to alleviate inflationary pressures on medical device manufacturers due to these disruptions. Additionally, the restoration of the Remission of Duties and Taxes on Exported Products (RoDTEP) scheme to its previous levels is expected to enhance the global competitiveness of Indian exports. However, shipping disruptions through key routes like the Strait of Hormuz continue to complicate logistics, potentially extending delivery timelines and impacting inventory buffers for pharmaceutical manufacturers.